Every 10-Q that LanzaTech Global, Inc. Warrant (LNZAW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LNZAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LNZAW filings page.
LanzaTech Global, Inc. reported six‑month 2026 revenue of $21.0 million, up from $18.6 million a year earlier, with biorefining and engineering services the main growth drivers. Operating performance improved significantly, as the loss from operations narrowed to $19.7 million from $63.3 million.
A large non‑operating gain from revaluing its investment in Beijing Shougang LanzaTech Technology (SGLT) produced a fair value gain on equity securities of $208.1 million. This more than offset operating losses and equity‑method losses from LanzaJet, leading to net income of $169.6 million versus a $51.7 million loss in the prior‑year period.
Liquidity strengthened: cash and cash equivalents were $45.0 million at June 30, 2026, up from $13.2 million at December 31, 2025, aided by $50.0 million of common stock issuances in January and May 2026. Shareholders’ equity swung from a $(3.9) million deficit to positive $260.6 million, primarily reflecting the SGLT revaluation and preferred‑stock conversion. The company states it projects being able to meet liquidity needs for the next twelve months.
LanzaTech Global, Inc. reported a narrower net loss and a strengthened balance sheet for the quarter ended March 31, 2026. Revenue rose to $12,020 thousand from $9,483 thousand, driven mainly by higher engineering services and grant-funded work, while research and development and selling, general and administrative expenses declined sharply.
Net loss improved to $14,679 thousand and operating cash outflow was $9,268 thousand. Cash, cash equivalents and restricted cash increased to $23,766 thousand, supported by a $20,000 thousand January 2026 private placement and conversion of preferred stock into common equity, which shifted shareholders’ equity from a deficit to positive $48,059 thousand.
The company settled its Forward Purchase Agreement liabilities, continues to carry an $11,000 thousand Brookfield Loan at fair value, and recorded a $4,549 thousand loss from its LanzaJet equity method investment. Management acknowledges historical losses but, considering recent financings and cost reductions, concludes it has sufficient liquidity for at least the next twelve months.
LanzaTech Global, Inc. reported unaudited interim results showing continuing losses and liquidity actions as it transitions from R&D to commercial deployment. The company had $37,367 in cash and cash equivalents and an accumulated deficit of $1,021,331 as of June 30, 2025. For the six months ended June 30, 2025 the company recorded a net loss of $51,728 and cash outflows from operations of $42,815.
The company closed a PIPE on May 7, 2025, issuing 20,000,000 shares of Series A Convertible Senior Preferred Stock for $40.0 million and, in connection with that financing, the company converted a $40.2 million principal Convertible Note into 34,054,337 shares of common stock. LanzaTech reported a fair value mark-to-market Brookfield Loan liability of $19,435 as of June 30, 2025 and disclosed a remaining contracted revenue backlog of approximately $19,198. Management states substantial doubt about the company’s ability to continue as a going concern absent additional capital or strategic options.